TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks
Brief Summary: Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: DRY group; Type: ACTIVE_COMPARATOR; Interventions: Other: Dry sheet Therapeutic body wraps | Arm Label: WET Group; Type: EXPERIMENTAL; Interventions: Other: WET sheet Therapeutic body wraps | Intervention Type: OTHER; Name: Dry sheet Therapeutic body wraps; Assigned to Arm(s): DRY group | Intervention Type: OTHER; Name: WET sheet Therapeutic body wraps; Assigned to Arm(s): WET Group
C: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
D: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks
Brief Summary: Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.


Options:
A: Arm Label: DRY group; Type: ACTIVE_COMPARATOR; Interventions: Other: Dry sheet Therapeutic body wraps | Arm Label: WET Group; Type: EXPERIMENTAL; Interventions: Other: WET sheet Therapeutic body wraps | Intervention Type: OTHER; Name: Dry sheet Therapeutic body wraps; Assigned to Arm(s): DRY group | Intervention Type: OTHER; Name: WET sheet Therapeutic body wraps; Assigned to Arm(s): WET Group
B: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
C: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks
Brief Summary: Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.


Options:
A: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
B: Intervention Type: DRUG; Name: Low Molecular Weight Heparin (dalteparin); Assigned to Arm(s): N/A
C: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nadroparin; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin | Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): Nadroparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation: Determining the Balance Between Benefits and Risks
Brief Summary: Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment during cast immobilization of the lower leg. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) during lower leg plaster cast immobilization following surgical or conservative treatment. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.


Options:
A: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
B: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: DRY group; Type: ACTIVE_COMPARATOR; Interventions: Other: Dry sheet Therapeutic body wraps | Arm Label: WET Group; Type: EXPERIMENTAL; Interventions: Other: WET sheet Therapeutic body wraps | Intervention Type: OTHER; Name: Dry sheet Therapeutic body wraps; Assigned to Arm(s): DRY group | Intervention Type: OTHER; Name: WET sheet Therapeutic body wraps; Assigned to Arm(s): WET Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation: Determining the Balance Between Benefits and Risks
Brief Summary: Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment during cast immobilization of the lower leg. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) during lower leg plaster cast immobilization following surgical or conservative treatment. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.


Options:
A: Arm Label: DRY group; Type: ACTIVE_COMPARATOR; Interventions: Other: Dry sheet Therapeutic body wraps | Arm Label: WET Group; Type: EXPERIMENTAL; Interventions: Other: WET sheet Therapeutic body wraps | Intervention Type: OTHER; Name: Dry sheet Therapeutic body wraps; Assigned to Arm(s): DRY group | Intervention Type: OTHER; Name: WET sheet Therapeutic body wraps; Assigned to Arm(s): WET Group
B: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
C: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation: Determining the Balance Between Benefits and Risks
Brief Summary: Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment during cast immobilization of the lower leg. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) during lower leg plaster cast immobilization following surgical or conservative treatment. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.


Options:
A: Intervention Type: DRUG; Name: Low Molecular Weight Heparin (dalteparin); Assigned to Arm(s): N/A
B: Arm Label: LMWH (Fragmin, dalteparin); Type: ACTIVE_COMPARATOR; Interventions: Drug: LMWH (Fragmin, dalteparin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: LMWH (Fragmin, dalteparin); Assigned to Arm(s): LMWH (Fragmin, dalteparin) | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): 2
C: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH
D: Arm Label: LMWH; Type: EXPERIMENTAL; Interventions: Drug: LMWH | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: LMWH; Assigned to Arm(s): LMWH

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Brief Summary: Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or radiotherapy. However, there are still debates on the clinical value of induction chemotherapy for patients with advanced and resectable oral squamous cell carcinoma. The hypothesis of this study is that the induction chemotherapy of TPF (docetaxel, cisplatin, and 5-fluorouracil) protocol could benefit the patients with locally advanced oral squamous cell carcinoma. The endpoints of this study are the survival rate, local control, and safety.


Options:
A: Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection
B: Arm Label: Surgery and radiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TPF induction chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: TPF induction chemotherapy | Intervention Type: DRUG; Name: TPF induction chemotherapy; Assigned to Arm(s): TPF induction chemotherapy
C: Arm Label: Ligusure assisted neck dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Neck dissection | Arm Label: Conventional neck dissection; Type: OTHER; Interventions: Procedure: Neck dissection | Intervention Type: PROCEDURE; Name: Neck dissection; Assigned to Arm(s): Conventional neck dissection, Ligusure assisted neck dissection
D: Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Brief Summary: Induction chemotherapy is regarded as an effective way to reduce or downgrade the locally advanced or aggressive cancers, and to improve the chance of eradication of the locoregional lesions by radical surgery and/or radiotherapy. However, there are still debates on the clinical value of induction chemotherapy for patients with advanced and resectable oral squamous cell carcinoma. The hypothesis of this study is that the induction chemotherapy of TPF (docetaxel, cisplatin, and 5-fluorouracil) protocol could benefit the patients with locally advanced oral squamous cell carcinoma. The endpoints of this study are the survival rate, local control, and safety.


Options:
A: Arm Label: Surgery and radiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TPF induction chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: TPF induction chemotherapy | Intervention Type: DRUG; Name: TPF induction chemotherapy; Assigned to Arm(s): TPF induction chemotherapy
B: Arm Label: Ligusure assisted neck dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Neck dissection | Arm Label: Conventional neck dissection; Type: OTHER; Interventions: Procedure: Neck dissection | Intervention Type: PROCEDURE; Name: Neck dissection; Assigned to Arm(s): Conventional neck dissection, Ligusure assisted neck dissection
C: Arm Label: Radiotherapy plus or minus Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy | Arm Label: Transoral Robotic Surgery + Neck Dissection; Type: EXPERIMENTAL; Interventions: Procedure: Transoral Robotic Surgery + Neck Dissection | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Radiotherapy plus or minus Chemotherapy | Intervention Type: PROCEDURE; Name: Transoral Robotic Surgery + Neck Dissection; Assigned to Arm(s): Transoral Robotic Surgery + Neck Dissection
D: Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
Brief Summary: This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.


Options:
A: Arm Label: Etanercept 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Etanercept 50 mg
B: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Matching Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab 200 mg, Drug: Tildrakizumab 100 mg, Drug: Matching Placebo | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Placebo, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg
C: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
D: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A